One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase ...

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...

Medipost transitioned from cord blood banking to developing stem cell therapies, focusing on knee osteoarthritis and other ...